page not found « sucampo  aboutmission vision  valueshistorycommunitymanagementboardlocationsscience  innovationpipelineregister as an investigative siteproductunited statesasiaeuropemenu iteminvestorspartneringour partnerspartnership opportunitiesnewscareerscareer opportunities  aboutaboutaboutmission vision  valueshistorycommunitymanagement oldboardlocationsscience  innovationscience  innovationscience  innovationpipelineregister as an investigative siteproductproductproducteuropeasiaunited statesinvestorsinvestorsinvestorsfinancials  sec filingsanalyst coveragestock informationevents  presentationscorporate governanceonline investor centerpartneringpartneringpartneringour partnerspartnership opportunitiesnewscareerscareerscareerscareer opportunitiesth december sucampo appoints john h johnson to board of directorsfiled under uncategorised — djm   ambethesda md december   globe newswire – sucampo pharmaceuticals inc sucampo nasdaq scmp a global biopharmaceutical company today announced the appointment of john h johnson founder plum brook advisors to its board of directors board “we are pleased to welcome john to our board during sucampo’s continued evolution” said peter greenleaf chief executive officer of sucampo “as a recognized leader in the biopharmaceutical industry who has tremendous experience in building and growing sciencefocused companies john will be instrumental as we continue to execute on our strategic objectives accelerate the development of our pipeline and diversify our science” mr johnson brings more than  years of leadership experience in the pharmaceutical and biotechnology industry to sucampo he has held executive management roles at leading global corporations including johnson  johnson eli lilly  company imclone and pfizer inc he recently served as a member of the board of directors of pharmaceutical research and manufacturers of america phrma and as a member of the health section governing board of biotechnology industry organization bio he also served as chairman president and chief executive officer of dendreon corporation and as chief executive officer and board member of savient pharmaceuticals inc prior to these roles mr johnson served as president of eli lilly  company’s oncology unit following its  acquisition of imclone systems inc where he served as chief executive officer and board member before joining imclone he held various executive roles of increasing responsibility including company group chairman of biopharmaceuticals at johnson  johnson where he was responsible for the johnson  johnson biotechnology immunology and oncology commercial businesses earlier in his career mr johnson held multiple executive positions at parkstone medical information systems inc orthomcneil pharmaceutical corp and pfizer inc mr johnson served as the chairman of tranzyme pharma inc and as a member of the board of bionj mr johnson currently serves as a member of the board of directors of cempra pharmaceuticals inc histogenics and portola pharmaceuticals “i am excited about the opportunity to join sucampo’s board of directors and leadership team” said john h johnson “i look forward to contributing to sucampo’s future growth and success developing and diversifying its pipeline and its delivery to patients in need and healthcare providers around the world” about sucampo pharmaceuticals inc sucampo pharmaceuticals inc is focused on the development and commercialization of medicines that meet major unmet medical needs of patients worldwide sucampo has two marketed products – amitiza® and rescula® – and a pipeline of drug candidates in clinical development a global company sucampo is headquartered in bethesda maryland and has operations in japan switzerland and the united kingdom for more information please visit wwwsucampocomthe sucampo logo is the registered trademark and the tagline the science of innovation is a registeredpending trademark of sucampo ag amitiza is a registered trademark of sucampo ag rescula is a registered trademark of rtech ueno ltd and has been licensed to sucampo ag follow us on twitter sucampopharma follow us on linkedin sucampo pharmaceuticals twitter linkedin sucampo forwardlooking statement this press release contains “forwardlooking statements” as that term is defined in the private securities litigation reform act of  these statements are based on management’s current expectations and involve risks and uncertainties which may cause results to differ materially from those set forth in the statements the forwardlooking statements may include statements regarding product development product potential future financial and operating results and other statements that are not historical facts the following factors among others could cause actual results to differ from those set forth in the forwardlooking statements the impact of pharmaceutical industry regulation and health care legislation sucampo’s ability to accurately predict future market conditions dependence on the effectiveness of sucampo’s patents and other protections for innovative products the risk of new and changing regulation and health policies in the us and internationally and the exposure to litigation andor regulatory actions no forwardlooking statement can be guaranteed and actual results may differ materially from those projected compare hotels sucampo undertakes no obligation to publicly update any forwardlooking statement whether as a result of new information future events or otherwise forwardlooking statements in this presentation should be evaluated together with the many uncertainties that affect sucampo’s business particularly those mentioned in the risk factors and cautionary statements in sucampo’s most recent forms k and k which sucampo incorporates by reference contact sucampo pharmaceuticals incsilvia taylorsenior vice president investor relations and corporate communicationsstaylorsucampocom comments th november sucampo pharmaceuticals announces webcast of its presentation at the th annual piper jaffray healthcare conferencefiled under uncategorised — djm   ambethesda md november   globe newswire – sucampo pharmaceuticals inc sucampo nasdaqscmp a global biopharmaceutical company today announced that it will webcast its corporate presentation at the th annual piper jaffray healthcare conference taking place tuesday december   at  am etthe presentation will be webcast live and may be accessed from the event calendar page of sucampo’s website at investorsucampocom  presentation slides will be available via the webcast links a replay of the webcast will also be available on the company’s website for several days after the live event to ensure a timely connection it is recommended that users register at least  minutes prior to the scheduled webcast about sucampo pharmaceuticals incsucampo pharmaceuticals inc is focused on the development and commercialization of medicines that meet major unmet medical needs of patients worldwide sucampo has two marketed products – amitiza® and rescula® – and a pipeline of drug candidates in clinical development a global company sucampo is headquartered in bethesda maryland and has operations in japan switzerland and the united kingdom for more information please visit wwwsucampocomthe sucampo logo is the registered trademark and the tagline the science of innovation is a registeredpending trademark of sucampo ag amitiza is a registered trademark of sucampo ag rescula is a registered trademark of rtech ueno ltd and has been licensed to sucampo ag follow us on twitter sucampopharma follow us on linkedin sucampo pharmaceuticalstwitter linkedin sucampo forwardlooking statement this press release contains “forwardlooking statements” as that term is defined in the private securities litigation reform act of  these statements are based on management’s current expectations and involve risks and uncertainties which may cause results to differ materially from those set forth in the statements the forwardlooking statements may include statements regarding product development product potential future financial and operating results and other statements that are not historical facts the following factors among others could cause actual results to differ from those set forth in the forwardlooking statements the impact of pharmaceutical industry regulation and health care legislation sucampo’s ability to accurately predict future market conditions dependence on the effectiveness of sucampo’s patents and other protections for innovative products the risk of new and changing regulation and health policies in the us and internationally and the exposure to litigation andor regulatory actions no forwardlooking statement can be guaranteed and actual results may differ materially from those projected satellite pictures sucampo undertakes no obligation to publicly update any forwardlooking statement whether as a result of new information future events or otherwise forwardlooking statements in this presentation should be evaluated together with the many uncertainties that affect sucampo’s business particularly those mentioned in the risk factors and cautionary statements in sucampo’s most recent form k and k which sucampo incorporates by reference contactsilvia taylorsenior vice president investor relations and corporate communicationssucampo pharmaceuticals incstaylorsucampocom comments th november sucampo files patent infringement lawsuit against dr reddy’sfiled under uncategorised — djm   ambethesda md november   globe newswire – sucampo pharmaceuticals inc nasdaq scmp a global biopharmaceutical company today announced that sucampo rtech ueno ltd takeda pharmaceutical company limited takeda and certain affiliates of takeda have filed a patent infringement lawsuit in the united states district court for the district of new jersey against dr reddy’s laboratories ltd and dr reddy’s laboratories inc collectively dr reddy’s related to an abbreviated new drug application anda that dr reddy’s filed with the us food and drug administration fda to market sell and use a generic version of the  mcg and  mcg amitiza® lubiprostone soft gelatin capsule products the lawsuit claims infringement of  patents that are listed in the fda’s orange book with the latest expiring in  sucampo commenced the lawsuit within  days from the receipt of a notice letter sent by dr reddy’s dated october   regarding its filing of its anda under the hatchwaxman act as a result of the patent infringement lawsuit final fda approval of dr reddy’s anda will be stayed up to  months from the date of receipt of the notice letter “protecting amitiza’s intellectual property is of paramount importance to sucampo” said peter greenleaf chief executive officer of sucampo “we believe that the amitiza patents granted by the us patent  trademark office are valid enforceable and infringed by dr reddy’s proposed lubiprostone products and we will vigorously defend them” about sucampo pharmaceuticals inc sucampo pharmaceuticals inc is focused on the development and commercialization of medicines that meet major unmet medical needs of patients worldwide sucampo has two marketed products – amitiza® and rescula® – and a pipeline of drug candidates in clinical development a global company sucampo is headquartered in bethesda maryland and has operations in japan switzerland and the united kingdom for more information please visit wwwsucampocomthe sucampo logo is the registered trademark and the tagline the science of innovation is a registeredpending trademark of sucampo ag amitiza is a registered trademark of sucampo ag rescula is a registered trademark of rtech ueno ltd and has been licensed to sucampo ag follow us on twitter sucampopharma follow us on linkedin sucampo pharmaceuticalstwitter linkedin sucampo forwardlooking statement this press release contains “forwardlooking statements” as that term is defined in the private securities litigation reform act of  these statements are based on management’s current expectations and involve risks and uncertainties which may cause results to differ materially from those set forth in the statements the forwardlooking statements may include statements regarding product development product potential future financial and operating results and other statements that are not historical facts the following factors among others could cause actual results to differ from those set forth in the forwardlooking statements the impact of pharmaceutical industry regulation and health care legislation sucampo’s ability to accurately predict future market conditions dependence on the effectiveness of sucampo’s patents and other protections for innovative products the risk of new and changing regulation and health policies in the us and internationally and the exposure to litigation andor regulatory actions no forwardlooking statement can be guaranteed and actual results may differ materially from those projected sucampo undertakes no obligation to publicly update any forwardlooking statement whether as a result of new information future events or otherwise forwardlooking statements in this presentation should be evaluated together with the many uncertainties that affect sucampo’s business particularly those mentioned in the risk factors and cautionary statements in sucampo’s most recent form k and k which sucampo incorporates by reference contactsilvia taylorsenior vice president investor relations and corporate communicationssucampo pharmaceuticals incstaylorsucampocom   comments th november sucampo pharmaceuticals announces webcast of its presentation at the stifel  healthcare conferencefiled under uncategorised — djm   ambethesda md november   globe newswire – sucampo pharmaceuticals inc sucampo nasdaqscmp a global biopharmaceutical company today announced that it will webcast its corporate presentation at the stifel  healthcare conference taking place tuesday november   at  pm etthe presentation will be webcast live and may be accessed from the event calendar page of sucampo’s website at httpinvestorsucampocomphoenixzhtmlcpirolcalendar presentation slides will be available via the webcast links a replay of the webcast will also be available on the company’s website for several days after the live event to ensure a timely connection it is recommended that users register at least  minutes prior to the scheduled webcast about sucampo pharmaceuticals incsucampo pharmaceuticals inc is focused on the development and commercialization of medicines that meet major unmet medical needs of patients worldwide sucampo has two marketed products – amitiza® and rescula® – and a pipeline of drug candidates in clinical development a global company sucampo is headquartered in bethesda maryland and has operations in japan switzerland and the united kingdom for more information please visit wwwsucampocomthe sucampo logo is the registered trademark and the tagline the science of innovation is a registeredpending trademark of sucampo ag amitiza is a registered trademark of sucampo ag rescula is a registered trademark of rtech ueno ltd and has been licensed to sucampo ag follow us on twitter sucampopharma follow us on linkedin sucampo pharmaceuticalstwitter linkedin sucampo forwardlooking statement this press release contains “forwardlooking statements” as that term is defined in the private securities litigation reform act of  these statements are based on management’s current expectations and involve risks and uncertainties which may cause results to differ materially from those set forth in the statements the forwardlooking statements may include statements regarding product development product potential future financial and operating results and other statements that are not historical facts the following factors among others could cause actual results to differ from those set forth in the forwardlooking statements the impact of pharmaceutical industry regulation and health care legislation sucampo’s ability to accurately predict future market conditions dependence on the effectiveness of sucampo’s patents and other protections for innovative products the risk of new and changing regulation and health policies in the us and internationally and the exposure to litigation andor regulatory actions no forwardlooking statement can be guaranteed and actual results may differ materially from those projected sucampo undertakes no obligation to publicly update any forwardlooking statement whether as a result of new information future events or otherwise forwardlooking statements in this presentation should be evaluated together with the many uncertainties that affect sucampo’s business particularly those mentioned in the risk factors and cautionary statements in sucampo’s most recent form k and k which sucampo incorporates by reference contactsilvia taylorsenior vice president investor relations and corporate communicationssucampo pharmaceuticals incstaylorsucampocom comments th november sucampo announces third quarter  financial resultsfiled under uncategorised — djm   amstrong revenue and sales growth for amitiza® raises  earnings guidance excluding special items ceo peter greenleaf to provide update on significant progress against strategic plan sucampo to host conference call today at  am eastern bethesda md november   globe newswire – sucampo pharmaceuticals inc sucampo nasdaq scmp today reported consolidated financial results for the third quarter and nine months ended september   sucampo reported year over year growth of  to  million in total revenue  to  million in product royalty revenue and  to  million in product sales sucampo also reported net income of  million and fullydiluted earnings per share eps of  during the third quarter of  sucampo raised its full year  earnings guidance to  million to  million net income excluding special items versus previous guidance of  million to  million during the third quarter of  sucampo recorded a noncash impairment to its intangible assets of  million to reflect a reduction in the expected future cash flows received from the sales of rescula for the approved indication which sucampo has ceased marketing and no further orders have been made details of the impairment charge are discussed in the cost of goods and rd expenses sections below sucampo is providing certain  nongaap information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends management believes that providing this information enhances investors’ understanding of sucampo’s performance this information should be considered in addition to but not in lieu of information prepared in accordance with gaapnet income is attributable to sucampo pharmaceuticals inc on a consolidated basis “in the third quarter sucampo’s strong financial performance continued and i am pleased that we made significant progress against our strategy” said peter greenleaf chief executive officer of sucampo “our total revenue grew  driven by amitiza’s continued growth in the us and japan the prospects for additional growth of the product are greater than ever given the agreements we signed this quarter creating a global partnership with takeda expanding the current amitiza agreement with takeda for north america and settling our generic litigation this is a time of great opportunity for sucampo as we continue to execute on our strategy with a focus on the development of our pipeline and the diversification of our science”   third quarter  operational review amitizaunited states us amitiza® lubiprostone total prescriptions were  an increase of  compared to the third quarter of  net sales of amitiza reported by takeda pharmaceuticals usa inc takeda for royalty calculation purposes increased  to  million for the third quarter of  compared to  million in the same period of  net sales of amitiza reported by takeda for royalty calculation purposes increased  to  million for the first nine months of  compared to  million in the same period of  launched a pilot directtoconsumer dtc advertising campaign with takeda in select us markets for amitiza sucampo takeda and rtech ueno ltd rtu entered into a settlement and license agreement with anchen pharmaceuticals inc par pharmaceutical inc and par pharmaceutical companies inc that resolved patent litigation among the parties related to amitiza  mcg and  mcg soft gelatin capsules signed an extension to our existing collaboration and license agreement with takeda covering the us and canada for amitiza global markets in japan sucampo’s revenue from sales of amitiza to abbott japan co ltd abbott for the third quarter of  was  million an increase of  million compared to the same period of  sucampo’s revenue from sales of amitiza to abbott for the first nine months of  was  million an increase of  million compared to the same period of  sucampo also announced that it had earned a  million milestone payment from abbott pursuant to the existing license commercialization and supply agreement the milestone payment was triggered by the first occurrence of annual net sales of lubiprostone for chronic idiopathic constipation cic in japan exceeding jpy  billion entered into a global license development commercialization and supply agreement for amitiza with takeda which expanded takeda’s exclusive rights to all global markets except japan and the people’s republic of china signed an exclusive global manufacturing and supply agreement with rtu for clinical and commercial supplies of amitiza in most global markets in the european union eu the mutual recognition procedure mrp started on october st to obtain approval in additional eu countries for amitiza for cic the mrp is anticipated to be completed in the first half of  in canada sucampo filed amitiza for the cic and opioidinduced constipation oic indications with health canada a decision is anticipated in the second half of  research and development in october four abstracts on lubiprostone were presented at the american college of gastroenterology  annual scientific meeting   corporate peter kiener d phil was appointed chief scientific officer matthias alder was appointed executive vice president business development  licensing steven caffé md was appointed senior vice president regulatory affairs cary claiborne chief financial officer cfo will leave sucampo on november  a search for a new cfo is ongoing third quarter  financial review net income was  million or  per diluted share for the third quarter of  compared to a net income of  million or  per diluted share in the same period in  net income was  million or  per diluted share for the first nine months of  compared to a net income of  million or  per diluted share in the same period in  total revenues were  million for the third quarter of  compared to  million in the same period in  an increase of  total revenues were  million for the first nine months of  compared to  million in the same period in  an increase of  the increase for both periods was primarily due to higher royalty revenue on amitiza net sales in the us and the growth of amitiza sales in japan as well as a  million milestone earned in japan the increase for the nine months in  royalty revenues and product sales from the same period in  were offset by the  receipt of the  million milestone payment from takeda upon the first commercial sale of amitiza for oic costs of goods sold were  million for the third quarter of  compared to  million for the same period of  a decrease of  the decrease was primarily due to a  million noncash writeoff of rescula inventory in the prior year period which did not reoccur partially offset by higher product purchases expenses as a result of increased volume of amitiza sales in japan costs of goods sold were  million for the first nine months of  compared to  million for the same period of  an increase of  the increase for the nine months was primarily due to increased volume of amitiza sales in japan partially offset by the  million noncash writeoff of rescula inventory in the prior year which did not reoccur intangible assets impairment was  million for the third quarter of  compared to nil for the same period of  the noncash impairment reflects a reduction in the expected future cash flows received from the sales of rescula in the fda approved indication which is no longer marketed and for which no orders have been placed for additional inventory rd expenses were  million for the third quarter of  compared to  million for the same period of  an increase of  rd expenses were  million for the first nine months of  compared to  million for the same period of  an increase of  the increase for both periods was primarily due to increased costs of our lubiprostone pediatric trial ga expenses were  million for the third quarter of  compared to  million for the same period of  an increase of  ga expenses were  million for the first nine months of  compared to  million for the same period of  an increase of  the increase for both periods was primarily due to a significant increase in legal fees incurred prosecuting a patent infringement lawsuit filed by us in february  the increase for the nine months was partially offset by a reduction in pharmacovigilance costs that were associated with launching amitiza in japan in  selling  marketing expenses were  million for the third quarter of  compared to  million for the same period of  a decrease of  selling  marketing expenses were  million for the first nine months of  compared to  million for the same period of  a decrease of  the decrease for both periods was primarily due to the replacement of our inhouse sales force with a lowercost contract sales force in  and a  million noncash writeoff of rescula in samples in the prior year that did not reoccur this year the decrease for the first nine months of  was partially offset by increased commercialization costs in europe for amitiza earnings excluding special items net income excluding special items for the third quarter of  was  million or  per diluted share compared to a net income of  million or  per diluted share in the third quarter of  net income excluding special items for the first nine months of  was  million or  per diluted share compared to a net income of  million or  per diluted share in the first nine months of  nongaap generally accepted accounting principles eps for the third quarter and nine months ended september   of  and  respectively exclude rescula intangible impairment a reconciliation of gaap to nongaap net income and eps is provided in the tables that follow represents the difference between calculated gaap eps and calculated nongaap eps which may be different than the amount calculated by dividing the impact of the excluded items by the weightedaverage shares for the period cash cash equivalents restricted cash and marketable securities at september   cash cash equivalents restricted cash and investments were  million compared to  million at december   at september   notes payable were  million compared to  million at december   including current notes payable of  million at september   and  million at december   guidance sucampo today increased its earnings guidance for  sucampo now expects full year  gaap net income excluding special items to be in the range of  million to  million or  to  per diluted share   company to host conference call today sucampo will host a conference call and webcast today at  am eastern to participate on the live call please dial  domestic or  international and provide the participant passcode  five to ten minutes ahead of the start of the call a replay of the call will be available within a few hours after the call ends investors may listen to the replay by dialing  domestic or  international passcode  investors interested in accessing the live audio webcast of the teleconference may do so at httpinvestorsucampocom and should log on before the teleconference begins in order to download any software required the archive of the teleconference will remain available for  daysabout lubiprostone amitiza® amitiza lubiprostone is a prostone and is a locally acting chloride channel activator indicated in the us for the treatment of cic in adults and oic in adults with chronic noncancer pain  mcg twice daily the effectiveness in patients with oic taking diphenylheptane opioids eg methadone has not been established amitiza is also indicated in the us for irritable bowel syndrome with constipation  mcg twice daily in women  years of age and older in japan amitiza  mcg twice daily is indicated for the treatment of chronic constipation excluding constipation caused by organic diseases in the united kingdom uk amitiza  mcg twice daily is indicated for the treatment of cic and associated symptoms in adults when response to diet and other nonpharmacological measures eg educational measures physical activity are inappropriate in switzerland amitiza  mcg twice daily is indicated for the treatment of cic in adults and for the treatment of oic and associated signs and symptoms such as stool consistency straining constipation severity abdominal discomfort and abdominal bloating in adults with chronic noncancer pain the efficacy of amitiza for the treatment of oic in patients taking opioids of the diphenylheptane class such as methadone has not been established about sucampo pharmaceuticals inc sucampo pharmaceuticals inc is focused on the development and commercialization of medicines that meet major unmet medical needs of patients worldwide sucampo has two marketed products – amitiza and rescula® – and a pipeline of product candidates in clinical development a global company sucampo is headquartered in bethesda maryland and has operations in japan switzerland and the uk for more information please visit wwwsucampocom the sucampo logo is the registered trademark and the tagline the science of innovation is a registeredpending trademark of sucampo ag amitiza is a registered trademark of sucampo ag rescula is a registered trademark of rtech ueno ltd and has been licensed to sucampo ag follow us on twitter sucampopharma follow us on linkedin sucampo pharmaceuticalstwitter linkedin sucampo forwardlooking statement this press release contains “forwardlooking statements” as that term is defined in the private securities litigation reform act of  these statements are based on management’s current expectations and involve risks and uncertainties which may cause results to differ materially from those set forth in the statements the forwardlooking statements may include statements regarding product development product potential future financial and operating results and other statements that are not historical facts the following factors among others could cause actual results to differ from those set forth in the forwardlooking statements the impact of pharmaceutical industry regulation and health care legislation the ability of sucampo to develop and commercialize existing and pipeline products sucampo’s ability to accurately predict future market conditions dependence on the effectiveness of sucampo’s patents and other protections for innovative products the risk of new and changing regulation and health policies in the us and internationally the effects of competitive products on sucampo’s products and the exposure to litigation andor regulatory actions no forwardlooking statement can be guaranteed and actual results may differ materially from those projected sucampo undertakes no obligation to publicly update any forwardlooking statement whether as a result of new information future events or otherwise forwardlooking statements in this presentation should be evaluated together with the many uncertainties that affect sucampo’s business particularly those mentioned in the risk factors and cautionary statements in sucampo’s most recent form k as filed with the securities and exchange commission on march   as well as its filings with the securities and exchange commission on form q and k which sucampo incorporates by reference contactsucampo pharmaceuticals incsilvia taylorsenior vice president investor relations and corporate communicationsstaylorsucampocom comments th november sucampo pharmaceuticals announces webcast of its presentation at the  credit suisse global healthcare conferencefiled under uncategorised — djm   ambethesda md november   globe newswire – sucampo pharmaceuticals inc sucampo nasdaqscmp a global biopharmaceutical company today announced that it will webcast its corporate presentation at the  credit suisse global healthcare conference taking place wednesday november   at  pm mountain time or  pm eastern timethe presentation will be webcast live and may be accessed from the event calendar page of sucampo’s website at httpinvestorsucampocomphoenixzhtmlcpirolcalendar presentation slides will be available via the webcast links a replay of the webcast will also be available on the company’s website for several days after the live event to ensure a timely connection it is recommended that users register at least  minutes prior to the scheduled webcast about sucampo pharmaceuticals inc sucampo pharmaceuticals inc is focused on the development and commercialization of medicines that meet major unmet medical needs of patients worldwide sucampo has two marketed products – amitiza® and rescula® – and a pipeline of drug candidates in clinical development a global company sucampo is headquartered in bethesda maryland and has operations in japan switzerland and the united kingdom for more information please visit wwwsucampocomthe sucampo logo is the registered trademark and the tagline the science of innovation is a registeredpending trademark of sucampo ag amitiza is a registered trademark of sucampo ag rescula is a registered trademark of rtech ueno ltd and has been licensed to sucampo ag follow us on twitter sucampopharma follow us on linkedin sucampo pharmaceuticalstwitter linkedin sucampo forwardlooking statement this press release contains “forwardlooking statements” as that term is defined in the private securities litigation reform act of  these statements are based on management’s current expectations and involve risks and uncertainties which may cause results to differ materially from those set forth in the statements the forwardlooking statements may include statements regarding product development product potential future financial and operating results and other statements that are not historical facts the following factors among others could cause actual results to differ from those set forth in the forwardlooking statements the impact of pharmaceutical industry regulation and health care legislation the ability of sucampo to develop and commercialize existing and pipeline products sucampo’s ability to accurately predict future market conditions dependence on the effectiveness of sucampo’s patents and other protections for innovative products the risk of new and changing regulation and health policies in the us and internationally and the exposure to litigation andor regulatory actions no forwardlooking statement can be guaranteed and actual results may differ materially from those projected sucampo undertakes no obligation to publicly update any forwardlooking statement whether as a result of new information future events or otherwise forwardlooking statements in this presentation should be evaluated together with the many uncertainties that affect sucampo’s business particularly those mentioned in the risk factors and cautionary statements in sucampo’s most recent form k as filed with the securities and exchange commission on march   as well as its filings with the securities and exchange commission on form q and k which sucampo incorporates by reference contactsilvia taylorsenior vice president investor relations and corporate communicationssucampo pharmaceuticals incstaylorsucampocom    comments th october sucampo pharmaceuticals inc announces third quarter  earnings callfiled under uncategorised — djm   ambethesda md october   globe newswire – sucampo pharmaceuticals inc sucampo nasdaq scmp a global biopharmaceutical company today announced that it will host its third quarter  financial results teleconference and webcast at  am eastern on thursday november   the press release announcing the financial results and operating highlights is expected to be released before the opening of capital markets that day individuals interested in accessing the live audio webcast of the teleconference may do so at httpinvestorsucampocomphoenixzhtmlcpirolcalendar and should log on  to  minutes before the teleconference begins to download any software required presentation slides will be available via the webcast link a replay of the webcast will also be available on sucampo’s website for several days after the live event alternatively individuals may dial  domestic or  international and use passcode  a replay of the teleconference will be available by dialing  domestic or  international passcode  approximately two hours after the teleconference concludes the archive of the teleconference will be available for  days about sucampo pharmaceuticals inc sucampo pharmaceuticals inc is focused on the development and commercialization of medicines that meet major unmet medical needs of patients worldwide sucampo has two marketed products – amitiza® and rescula® – and a pipeline of drug candidates in clinical development a global company sucampo is headquartered in bethesda maryland and has operations in japan switzerland and the united kingdom for more information please visit wwwsucampocomthe sucampo logo is the registered trademark and the tagline the science of innovation is a registeredpending trademark of sucampo ag amitiza is a registered trademark of sucampo ag rescula is a registered trademark of rtech ueno ltd and has been licensed to sucampo ag follow us on twitter sucampopharma follow us on linkedin sucampo pharmaceuticalstwitter linkedin sucampo forwardlooking statement this press release contains “forwardlooking statements” as that term is defined in the private securities litigation reform act of  these statements are based on management’s current expectations and involve risks and uncertainties which may cause results to differ materially from those set forth in the statements the forwardlooking statements may include statements regarding product development product potential future financial and operating results and other statements that are not historical facts the following factors among others could cause actual results to differ from those set forth in the forwardlooking statements the impact of pharmaceutical industry regulation and health care legislation the ability of sucampo to develop and commercialize existing and pipeline products sucampo’s ability to accurately predict future market conditions dependence on the effectiveness of sucampo’s patents and other protections for innovative products the risk of new and changing regulation and health policies in the us and internationally and the exposure to litigation andor regulatory actions no forwardlooking statement can be guaranteed and actual results may differ materially from those projected sucampo undertakes no obligation to publicly update any forwardlooking statement whether as a result of new information future events or otherwise forwardlooking statements in this presentation should be evaluated together with the many uncertainties that affect sucampo’s business particularly those mentioned in the risk factors and cautionary statements in sucampo’s most recent form k as filed with the securities and exchange commission on march   as well as its filings with the securities and exchange commission on form q and k which sucampo incorporates by reference contactsilvia taylorsenior vice president investor relations and corporate communicationssucampo pharmaceuticals incstaylorsucampocom  comments rd october sucampo solidifies leadership team with additions of cso and heads of business development regulatory affairsfiled under uncategorised — djm   ambethesda md october   globe newswire – sucampo pharmaceuticals inc sucampo nasdaq scmp a global biopharmaceutical company today announced three executive appointments that expand and solidify the leadership team in line with the company’s strategic plan the appointments are peter kiener dphil             as chief scientific officer cso matthias alder as executive vice president business development and licensing and steven caffé md as senior vice president regulatory affairs “we are building a stronger focused company and filling our key leadership roles with these highcaliber executives is essential for sucampo’s continued evolution” said peter greenleaf chief executive officer of sucampo “the addition of tenured biopharmaceutical executives gives us the depth of scientific leadership to expedite our company’s transformation and to execute on our priorities of leveraging sucampo’s strengths in drug development securing and growing revenue from sales of amitiza increasing our pace of current pipeline development and diversifying our portfolio through the acquisition of new science each of the new executives brings to sucampo functional expertise and a track record of success and each of them sees as i do the potential of our strategic vision for sucampo” dr kiener is recognized for his expertise in the development of nextgeneration biologics most recently he was cso of ambrx inc a clinicalstage biopharmaceutical company focused on the development of antibodydrug conjugates prior to joining ambrx dr kiener was president and cofounder of zyngenia inc an early stage biopharmaceutical company before this he was executive vice president and global head of biologics research and development at medimmune llc the global biologics arm of astrazeneca during his tenure there dr kiener assisted with building the company’s industryleading protein and antibody engineering capabilities and oversaw the submission of multiple investigational new drug and new drug applications earlier in his career he held multiple positions at bristolmyers squibb over an year period where he worked on biologics dr kiener has served on the scientific advisory boards of kai pharmaceuticals inc genocea biosciences inc nkt therapeutics inc and vlst corporation dr kiener has also served as a director of receptor biologix inc synovex corporation and virdante pharmaceuticals inc he received his bachelor’s degree in chemistry from the university of lancaster and doctorate of philosophy in biochemistry from the university of oxford dr kiener has published more than  papers in peerreviewed journals and is an inventor on more than  patents and patent applications mr alder brings more than  years of industry experience to sucampo most recently he was executive vice president of corporate development and legal affairs and corporate secretary at cytos biotechnology ag a biopharmaceutical company focused on the development of targeted immunotherapies prior to joining cytos he held various roles of increasing responsibility including senior vice president administration general counsel and secretary of micromet inc which was acquired by amgen prior to this mr alder was a partner in the life sciences transactions practice at cooley llp where he represented biotech companies in strategic transactions with pharmaceutical companies earlier in his career mr alder was inhouse counsel at cibageigy and novartis he holds law degrees from the university of basel and the university of miami and is qualified to practice law in switzerland and the us dr caffé brings more than  years of global product development registration and lifecycle management expertise to the company prior to joining sucampo he was senior vice president and chief development and regulatory officer at amag pharmaceuticals inc a specialty pharmaceutical company where he played a key role in the provision of strategic insight and operational expertise to ensure successful product development and advancement and in the acquisition of assets prior to joining amag dr caffé was senior vice president head of global regulatory affairs and patient safety at medimmune at medimmune he was responsible for all regulatory and pharmacovigilance matters for commercial and pipeline products prior to this he held increasing leadership positions at baxter international inc sanofi and merck  co through various regulatory and development programs he secured product approvals while building and leading highperforming global teams dr caffé received his medical degree from the faculté de médecine saintantoine université pierre et marie curie paris  and completed his internship and residency and practiced medicine at the academic hospitals of the assistance publique de paris with a focus on emergency and intensive care about sucampo pharmaceuticals inc sucampo pharmaceuticals inc is focused on the development and commercialization of medicines that meet major unmet medical needs of patients worldwide sucampo has two marketed products – amitiza® and rescula® – and a pipeline of product candidates in clinical development a global company sucampo is headquartered in bethesda maryland and has operations in japan switzerland and the uk for more information please visit wwwsucampocomthe sucampo logo is the registered trademark and the tagline the science of innovation is a registeredpending trademark of sucampo ag amitiza is a registered trademark of sucampo ag rescula is a registered trademark of rtech ueno ltd and has been licensed to sucampo ag follow us on twitter sucampopharma follow us on linkedin sucampo pharmaceuticals twitter linkedin sucampo forwardlooking statement this press release contains “forwardlooking statements” as that term is defined in the private securities litigation reform act of  these statements are based on management’s current expectations and involve risks and uncertainties which may cause results to differ materially from those set forth in the statements the forwardlooking statements may include statements regarding product development product potential future financial and operating results and other statements that are not historical facts the following factors among others could cause actual results to differ from those set forth in the forwardlooking statements the impact of pharmaceutical industry regulation and health care legislation sucampo’s ability to accurately predict future market conditions dependence on the effectiveness of sucampo’s patents and other protections for innovative products the risk of new and changing regulation and health policies in the us and internationally and the exposure to litigation andor regulatory actions no forwardlooking statement can be guaranteed and actual results may differ materially from those projected sucampo undertakes no obligation to publicly update any forwardlooking statement whether as a result of new information future events or otherwise forwardlooking statements in this presentation should be evaluated together with the many uncertainties that affect sucampo’s business particularly those mentioned in the risk factors and cautionary statements in sucampo’s most recent form k and k which sucampo incorporates by reference contactsucampo pharmaceuticals incsilvia taylorsenior vice president investor relations and corporate communicationsstaylorsucampocom comments st october takeda and sucampo enter into global licensing agreement for amitiza® lubiprostonefiled under uncategorised — djm   amtakeda gains exclusive rights to amitiza beyond us and canada for all markets except japan and china  bethesda md october   and osaka japan october   globe newswire – sucampo pharmaceuticals inc sucampo nasdaq scmp a global biopharmaceutical company and takeda pharmaceutical company limited takeda today announced that on october   they entered into a global license development commercialization and supply agreement for amitiza® lubiprostone through this agreement takeda expanded its exclusive rights beyond the united states us and canada to further develop and commercialize amitiza in all global markets except japan and the people’s republic of china “takeda is committed to being a patient and customercentric organization making quality health products available to the patients who need them through this agreement amitiza can now be made available to patients worldwide” said shinji honda senior managing director and corporate strategy officer “takeda forms partnerships to advance science and to provide innovative treatment options for patients and this global agreement is an excellent example this global collaboration leverages the expertise we have established through our gastroenterology portfolio of products” “the expansion of our collaboration with takeda represents a critical step forward with our strategic plan and is the natural evolution of our partnership with them for north america” said peter greenleaf chief executive officer of sucampo “this agreement allows sucampo to remain focused on our strengths in drug development while allowing us to make amitiza available to more patients in need around the world we are confident that with the combination of their extensive experience with amitiza and proven global infrastructure that takeda will build the brand in new global markets as they have done in the us where amitiza continues to grow steadily” under the terms of the agreement sucampo will receive an upfront payment of  million from takeda and will also be eligible for up to  million in additional commercial milestones contingent on the achievement of certain net sales revenue targets additionally sucampo will be the exclusive supplier of amitiza to takeda at an agreedupon supply price takeda will be responsible for all development activities and costs with sucampo assuming responsibility for the first  million in development expenses in addition takeda will become the marketing authorization holder and will be responsible for all commercialization and regulatory activities about amitiza lubiprostone amitiza lubiprostone is a prostone and is a locally acting chloride channel activator indicated in the united states for the treatment of chronic idiopathic constipation cic in adults and opioidinduced constipation oic in adults with chronic noncancer pain  mcg twice daily the effectiveness in patients with oic taking diphenylheptane opioids eg methadone has not been established amitiza is also indicated in the us for irritable bowel syndrome with constipation ibsc  mcg twice daily in women  years of age and older important safety informationamitiza lubiprostone is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction patients with symptoms suggestive of mechanical gastrointestinal obstruction should be thoroughly evaluated by the treating healthcare provider hcp to confirm the absence of such an obstruction prior to initiating amitiza treatment patients taking amitiza may experience nausea if this occurs concomitant administration of food with amitiza may reduce symptoms of nausea patients who experience severe nausea should inform their hcp amitiza should not be prescribed to patients that have severe diarrhea patients should be aware of the possible occurrence of diarrhea during treatment patients should be instructed to discontinue amitiza and inform their hcp if severe diarrhea occurs patients taking amitiza may experience dyspnea within an hour of first dose this symptom generally resolves within three hours but may recur with repeat dosing patients who experience dyspnea should inform their hcp some patients have discontinued therapy because of dyspnea in clinical trials of amitiza  mcg twice daily vs placebo n vs n respectively in patients with cic the most common adverse reactions incidence   were nausea  vs  diarrhea  vs  headache  vs  abdominal pain  vs  abdominal distension  vs  and flatulence  vs  in clinical trials of amitiza  mcg twice daily vs placebo n vs n respectively in patients with oic the most common adverse reactions incidence  were nausea  vs  and diarrhea  vs  in clinical trials of amitiza  mcg twice daily vs placebo n vs n respectively in patients with ibsc the most common adverse reactions incidence   were nausea  vs  diarrhea  vs  and abdominal pain  vs  concomitant use of diphenylheptane opioids eg methadone may interfere with the efficacy of amitiza the safety of amitiza in pregnancy has not been evaluated in humans based on animal data amitiza may cause fetal harm amitiza should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus caution should be exercised when amitiza is administered to a nursing woman advise nursing women to monitor infants for diarrhea reduce the dosage in cic and oic patients with moderate and severe hepatic impairment reduce the dosage in ibsc patients with severe hepatic impairment please see the full prescribing information here for further information on amitiza please visit wwwsucampocomproducts about sucampo pharmaceuticals incsucampo pharmaceuticals inc is focused on the development and commercialization of medicines that meet major unmet medical needs of patients worldwide sucampo has two marketed products – amitiza® and rescula® – and a pipeline of product candidates in clinical development a global company sucampo is headquartered in bethesda maryland and has operations in japan switzerland and the united kingdom for more information please visit wwwsucampocom the sucampo logo is the registered trademark and the tagline the science of innovation is a pending trademark of sucampo ag amitiza is a registered trademark of sucampo ag rescula is a registered trademark of rtech ueno ltd and has been licensed to sucampo ag follow us on twitter sucampopharma follow us on linkedin sucampo pharmaceuticals twitter linkedin sucampo forwardlooking statement this press release contains “forwardlooking statements” as that term is defined in the private securities litigation reform act of  these statements are based on management’s current expectations and involve risks and uncertainties which may cause results to differ materially from those set forth in the statements the forwardlooking statements may include statements regarding product development product potential future financial and operating results and other statements that are not historical facts the following factors among others could cause actual results to differ from those set forth in the forwardlooking statements the impact of pharmaceutical industry regulation and health care legislation the ability of sucampo to develop and commercialize existing and pipeline products sucampo’s ability to accurately predict future market conditions dependence on the effectiveness of sucampo’s patents and other protections for innovative products the risk of new and changing regulation and health policies in the us and internationally the effects of competitive products on sucampo’s products and the exposure to litigation andor regulatory actions no forwardlooking statement can be guaranteed and actual results may differ materially from those projected sucampo undertakes no obligation to publicly update any forwardlooking statement whether as a result of new information future events or otherwise forwardlooking statements in this presentation should be evaluated together with the many uncertainties that affect sucampo’s business particularly those mentioned in the risk factors and cautionary statements in sucampo’s most recent form k as filed with the securities and exchange commission on march   as well as its filings with the securities and exchange commission on form q and k which sucampo incorporates by reference about takeda pharmaceutical company limited located in osaka japan takeda is a researchbased global company with its main focus on pharmaceuticals as the largest pharmaceutical company in japan and one of the global leaders of the industry takeda is committed to strive towards better health for people worldwide through leading innovation in medicine additional information about takeda is available through its corporate website wwwtakedacom takeda forwardlooking statement this press release contains forwardlooking statements forwardlooking statements include statements regarding takeda’s plans outlook strategies results for the future and other statements that are not descriptions of historical facts forwardlooking statements may be identified by the use of forwardlooking words such as “may” “believe” “will” “expect” “project” “estimate” “should” “anticipate” “plan” “assume” “continue” “seek” “pro forma” “potential” “target” “forecast” “guidance” “outlook” or “intend” or other similar words or expressions of the negative thereof forwardlooking statements are based on estimates and assumptions made by management that are believed to be reasonable though they are inherently uncertain and difficult to predict investors are cautioned not to unduly rely on such forwardlooking statements forwardlooking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forwardlooking statements some of these risks and uncertainties include but are not limited to  the economic circumstances surrounding takeda’s business including general economic conditions in japan the us and worldwide  competitive pressures and developments  applicable laws and regulations  the success or failure of product development programs  actions of regulatory authorities and the timing thereof  changes in exchange rates  claims or concerns regarding the safety or efficacy of marketed products or product candidates in development and  integration activities with acquired companies the forwardlooking statements contained in this press release speak only as of the date of this press release and takeda undertakes no obligation to revise or update any forwardlooking statements to reflect new information future events or circumstances after the date of the forwardlooking statement if takeda does update or correct one or more of these statements investors and others should not conclude that takeda will make additional updates or corrections contact sucampo pharmaceuticals incsilvia taylorsenior vice president investor relations and corporate communicationsstaylorsucampocom takeda pharmaceutical company limitedcorporate communications depttel  takeda pharmaceuticals international incjocelyn gerstcorporate communications depttel  comments th october clinical data for amitiza® lubiprostone to be presented at the american college of gastroenterology  annual scientific meetingfiled under uncategorised — djm   ambethesda md october   globe newswire – sucampo pharmaceuticals inc sucampo nasdaq scmp a global biopharmaceutical company today announced that clinical data for amitiza® lubiprostone will be presented at the american college of gastroenterology acg  annual scientific meeting on sunday october  and monday october  at the pennsylvania convention center in philadelphia poster presentations the following abstracts will be presented at acg  sunday oct  from  pm to  pm edtweek  response predicts durable response to lubiprostone in patients with chronic idiopathic constipation ayesha akbar mbchb hons mrcp phd taryn loschberidon bs martin wang ms peter lichtlen md phdposter no p impact of methadone dose and baseline bowel movement frequency on efficacy of lubiprostone for opioidinduced constipation byron cryer md peter lichtlen md phd martin wang ms taryn loschberidon bsposter no pmonday oct  from  am to  pm edteffects of lubiprostone in patients with chronic idiopathic and opioidinduced constipation on serum electrolytes and markers of renal function satish s c rao md phd facg egilius l h spierings md phd john f johanson md msc facp facg peter lichtlen md phd sepideh habibi mdposter no p lubiprostone for treatment of opioidinduced constipation analysis of influencing factors taryn loschberidon bs peter lichtlen md phd martin wang msposter no p about amitiza lubiprostone amitiza lubiprostone is a prostone and is a locally acting chloride channel activator indicated in the united states for the treatment of chronic idiopathic constipation cic in adults and opioidinduced constipation oic in adults with chronic noncancer pain  mcg twice daily the effectiveness in patients with oic taking diphenylheptane opioids eg methadone has not been established amitiza is also indicated in the us for irritable bowel syndrome with constipation ibsc  mcg twice daily in women  years of age and older important safety informationamitiza lubiprostone is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction patients with symptoms suggestive of mechanical gastrointestinal obstruction should be thoroughly evaluated by the treating healthcare provider hcp to confirm the absence of such an obstruction prior to initiating amitiza treatment patients taking amitiza may experience nausea if this occurs concomitant administration of food with amitiza may reduce symptoms of nausea patients who experience severe nausea should inform their hcp amitiza should not be prescribed to patients that have severe diarrhea patients should be aware of the possible occurrence of diarrhea during treatment patients should be instructed to discontinue amitiza and inform their hcp if severe diarrhea occurs patients taking amitiza may experience dyspnea within an hour of first dose this symptom generally resolves within three hours but may recur with repeat dosing patients who experience dyspnea should inform their hcp some patients have discontinued therapy because of dyspnea in clinical trials of amitiza  mcg twice daily vs placebo n vs n respectively in patients with cic the most common adverse reactions incidence   were nausea  vs  diarrhea  vs   headache  vs  abdominal pain  vs  abdominal distension  vs  and flatulence  vs  in clinical trials of amitiza  mcg twice daily vs placebo n vs n in patients with oic the most common adverse reactions incidence   were nausea  vs  and diarrhea  vs  in clinical trials of amitiza  mcg twice daily vs placebo n vs n respectively in patients with ibsc the most common adverse reactions incidence   were nausea  vs  diarrhea  vs  and abdominal pain  vs  concomitant use of diphenylheptane opioids eg methadone may interfere with the efficacy of amitiza the safety of amitiza in pregnancy has not been evaluated in humans based on animal data amitiza may cause fetal harm amitiza should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus caution should be exercised when amitiza is administered to a nursing woman advise nursing women to monitor infants for diarrhea reduce the dosage in cic and oic patients with moderate and severe hepatic impairment reduce the dosage in ibsc patients with severe hepatic impairment please see the full prescribing information here for further information on amitiza please visit wwwsucampocomproducts about sucampo pharmaceuticals incsucampo pharmaceuticals inc is focused on the development and commercialization of medicines to meet the major unmet medical needs of patients on a global basis sucampo has two marketed products – amitiza® and rescula® – and a pipeline of product candidates in clinical development a global company sucampo is headquartered in bethesda maryland and has operations in japan switzerland and the uk for more information please visit wwwsucampocom the sucampo logo is the registered trademark and the tagline the science of innovation is a pending trademark of sucampo ag amitiza is a registered trademark of sucampo ag rescula is a registered trademark of rtech ueno ltd and has been licensed to sucampo ag follow us on twitter sucampopharma follow us on linkedin sucampo pharmaceuticals twitter linkedin sucampo forwardlooking statement this press release contains “forwardlooking statements” as that term is defined in the private securities litigation reform act of  these statements are based on management’s current expectations and involve risks and uncertainties which may cause results to differ materially from those set forth in the statements the forwardlooking statements may include statements regarding product development product potential future financial and operating results and other statements that are not historical facts the following factors among others could cause actual results to differ from those set forth in the forwardlooking statements the impact of pharmaceutical industry regulation and health care legislation sucampo’s ability to accurately predict future market conditions dependence on the effectiveness of sucampo’s patents and other protections for innovative products the risk of new and changing regulation and health policies in the us and internationally and the exposure to litigation andor regulatory actions no forwardlooking statement can be guaranteed and actual results may differ materially from those projected sucampo undertakes no obligation to publicly update any forwardlooking statement whether as a result of new information future events or otherwise forwardlooking statements in this presentation should be evaluated together with the many uncertainties that affect sucampo’s business particularly those mentioned in the risk factors and cautionary statements in sucampo’s most recent form k and k which sucampo incorporates by reference contactsucampo pharmaceuticals incsilvia taylorsenior vice president investor relations and corporate communicationsstaylorsucampocom  comments th october sucampo announces extension of amitiza® lubiprostone license and collaboration agreement with takedafiled under uncategorised — djm   ambethesda md october   globe newswire – sucampo pharmaceuticals inc sucampo nasdaq scmp a global biopharmaceutical company today announced that it signed on october   an amendment to the existing collaboration and license agreement collaboration agreement covering the united states us and canada for amitiza® lubiprostone with takeda pharmaceutical company ltd takeda the amendment includes various modifications to the collaboration agreement including the extension of the current term minimum commercial investment during the current term and various governance changes allowing takeda additional flexibility in commercializing amitiza during the extended term which will begin on january   takeda will split with sucampo the gross profits of branded amitiza for any dosage strength and form for the existing indications in the us and canada in addition on april   takeda will no longer reimburse sucampo for the product details made by sucampo sales representatives to healthcare professionals as well as other ancillary costs of the sales force “today’s announcement of the extended collaboration with takeda is yet another step toward achieving our objective of securing sucampo’s foundation and expanding the amitiza business this extended collaboration also allows sucampo to share in the longterm value of amitiza” said peter greenleaf chief executive officer of sucampo “takeda and sucampo are aligned in our objectives for the brand and i believe this newly extended collaboration and license agreement positions the companies more strongly than ever to help grow the amitiza business”  about amitiza lubiprostone amitiza lubiprostone is a prostone and is a locally acting chloride channel activator indicated in the us for the treatment of chronic idiopathic constipation cic in adults and opioidinduced constipation oic in adults with chronic noncancer pain  mcg twice daily the effectiveness in patients with oic taking diphenylheptane opioids eg methadone has not been established amitiza is also indicated in the us for irritable bowel syndrome with constipation ibsc  mcg twice daily in women  years of age and older important safety informationamitiza lubiprostone is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction patients with symptoms suggestive of mechanical gastrointestinal obstruction should be thoroughly evaluated by the treating healthcare provider hcp to confirm the absence of such an obstruction prior to initiating amitiza treatment patients taking amitiza may experience nausea if this occurs concomitant administration of food with amitiza may reduce symptoms of nausea patients who experience severe nausea should inform their hcp amitiza should not be prescribed to patients that have severe diarrhea patients should be aware of the possible occurrence of diarrhea during treatment patients should be instructed to discontinue amitiza and inform their hcp if severe diarrhea occurs patients taking amitiza may experience dyspnea within an hour of first dose this symptom generally resolves within three hours but may recur with repeat dosing patients who experience dyspnea should inform their hcp some patients have discontinued therapy because of dyspnea in clinical trials of amitiza  mcg twice daily vs placebo n vs n respectively in patients with cic the most common adverse reactions incidence   were nausea  vs  diarrhea  vs  headache  vs  abdominal pain  vs  abdominal distension  vs  and flatulence  vs  in clinical trials of amitiza  mcg twice daily vs placebo n vs n respectively in patients with oic the most common adverse reactions incidence  were nausea  vs  and diarrhea  vs  in clinical trials of amitiza  mcg twice daily vs placebo n vs n respectively in patients with ibsc the most common adverse reactions incidence   were nausea  vs  diarrhea  vs  and abdominal pain  vs  concomitant use of diphenylheptane opioids eg methadone may interfere with the efficacy of amitiza the safety of amitiza in pregnancy has not been evaluated in humans based on animal data amitiza may cause fetal harm amitiza should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus caution should be exercised when amitiza is administered to a nursing woman advise nursing women to monitor infants for diarrhea reduce the dosage in cic and oic patients with moderate and severe hepatic impairment reduce the dosage in ibsc patients with severe hepatic impairment please see the full prescribing information here for further information on amitiza please visit wwwsucampocomproducts about sucampo pharmaceuticals incsucampo pharmaceuticals inc is focused on the development and commercialization of medicines that meet major unmet medical needs of patients worldwide sucampo has two marketed products – amitiza® and rescula® – and a pipeline of product candidates in clinical development a global company sucampo is headquartered in bethesda maryland and has operations in japan switzerland and the uk for more information please visit wwwsucampocom the sucampo logo is the registered trademark and the tagline the science of innovation is a pending trademark of sucampo ag amitiza is a registered trademark of sucampo ag rescula is a registered trademark of rtech ueno ltd and has been licensed to sucampo ag follow us on twitter sucampopharma follow us on linkedin sucampo pharmaceuticals twitter linkedin sucampo forwardlooking statement this press release contains “forwardlooking statements” as that term is defined in the private securities litigation reform act of  these statements are based on management’s current expectations and involve risks and uncertainties which may cause results to differ materially from those set forth in the statements the forwardlooking statements may include statements regarding product development product potential future financial and operating results and other statements that are not historical facts the following factors among others could cause actual results to differ from those set forth in the forwardlooking statements the impact of pharmaceutical industry regulation and health care legislation sucampo’s ability to accurately predict future market conditions dependence on the effectiveness of sucampo’s patents and other protections for innovative products the risk of new and changing regulation and health policies in the us and internationally and the exposure to litigation andor regulatory actions no forwardlooking statement can be guaranteed and actual results may differ materially from those projected sucampo undertakes no obligation to publicly update any forwardlooking statement whether as a result of new information future events or otherwise forwardlooking statements in this presentation should be evaluated together with the many uncertainties that affect sucampo’s business particularly those mentioned in the risk factors and cautionary statements in sucampo’s most recent form k and k which sucampo incorporates by reference contactsucampo pharmaceuticals incsilvia taylorsenior vice president investor relations and corporate communicationsstaylorsucampocom  comments th october sucampo announces settlement agreement that resolves patent litigation in us related to amitizafiled under uncategorised — djm   amcompany receives additional paragraph iv notice bethesda maryland october   globe newswire — sucampo pharmaceuticals inc sucampo nasdaq scmp a global biopharmaceutical company today announced that sucampo rtech ueno ltd rtu takeda pharmaceutical company limited takeda and certain affiliates of takeda have entered into a settlement and license agreement with anchen pharmaceuticals inc par pharmaceutical inc and par pharmaceutical companies inc collectively par that resolves patent litigation in the united states us related to sucampo’s amitiza® lubiprostone  mcg and  mcg soft gelatin capsules under the terms of the settlement sucampo and rtu will grant par a nonexclusive license to market par’s generic version of lubiprostone  mcg soft gelatin capsule and  mcg soft gelatin capsule licensed products in the us for the indications approved for amitiza beginning january   or earlier under certain circumstances beginning on january   par will split with sucampo the gross profits of the licensed products sold during the term of the agreement which continues until each of the sucampo patents has expired in the event par elects to launch an authorized generic sucampo will supply par under the terms of a manufacturing and supply agreement at a negotiated price additional details of the agreement remain confidential “this settlement agreement is an important step for sucampo toward securing our foundation and continuing to grow sales of amitiza” said peter greenleaf chief executive officer of sucampo “we are on track with the strategic imperatives i communicated in august that include a sharp focus on our flagship product this is not only beneficial to our company and shareholders it is important to prescribing physicians and their patients who depend on amitiza for treatment” sucampo rtu takeda and par have agreed to dismiss with prejudice the patent litigation filed in the us district court for the district of delaware additionally sucampo said it has received a paragraph iv certification notice letter notice letter regarding an abbreviated new drug application anda submitted to the us food and drug administration fda by dr reddy’s laboratories inc dr reddy’s requesting approval to market sell and use a generic version of the  mcg and  mcg amitiza® lubiprostone soft gelatin capsule products sucampo is currently reviewing the notice letter by statute if sucampo initiates a patent infringement lawsuit against dr reddy’s within  days of the notice date the fda would automatically stay approval of the dr reddy’s anda until the earlier of  months from the notice date or entry of a district court decision finding the patents invalid or not infringed the product is currently protected by  issued patents that are listed in the fda’s orange book with the latest expiring in  “we will continue to vigorously enforce amitiza’s intellectual property rights” said greenleaf “generic companies have made paragraph iv certifications a routine part of business sucampo is well prepared to pursue all legal pathways in defense of amitiza” about sucampo pharmaceuticals inc sucampo pharmaceuticals inc is focused on the development and commercialization of medicines that meet unmet medical needs of patients worldwide sucampo has two marketed products – amitiza® and rescula® – and a pipeline of product candidates in clinical development a global company sucampo is headquartered in bethesda maryland and has operations in japan switzerland and the united kingdom for more information please visit wwwsucampocomthe sucampo logo is the registered trademark and the tagline the science of innovation is a pending trademark of sucampo ag amitiza is a registered trademark of sucampo ag rescula is a registered trademark of rtech ueno ltd and has been licensed to sucampo ag follow us on twitter sucampopharma follow us on linkedin sucampo pharmaceuticals twitter linkedin sucampo forwardlooking statement this press release contains “forwardlooking statements” as that term is defined in the private securities litigation reform act of  these statements are based on management’s current expectations and involve risks and uncertainties which may cause results to differ materially from those set forth in the statements the forwardlooking statements may include statements regarding product development product potential future financial and operating results and other statements that are not historical facts the following factors among others could cause actual results to differ from those set forth in the forwardlooking statements the impact of pharmaceutical industry regulation and health care legislation sucampo’s ability to accurately predict future market conditions dependence on the effectiveness of sucampo’s patents and other protections for innovative products the risk of new and changing regulation and health policies in the us and internationally and the exposure to litigation andor regulatory actions no forwardlooking statement can be guaranteed and actual results may differ materially from those projected sucampo undertakes no obligation to publicly update any forwardlooking statement whether as a result of new information future events or otherwise forwardlooking statements in this presentation should be evaluated together with the many uncertainties that affect sucampo’s business particularly those mentioned in the risk factors and cautionary statements in sucampo’s most recent form k and k which sucampo incorporates by reference contactsucampo pharmaceuticals incsilvia taylorsenior vice president investor relations and corporate communicationsstaylorsucampocom comments contact us tel sucampo pharmaceuticals inc  king farm boulevard suite  rockville maryland infosucampocom  sucampo pharmaceuticals inc is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide sucampo has two marketed products – amitiza its lead product and rescula – and a latestage pipeline of product candidates in clinical development for orphan disease areas vts is a mixture of hydroxypropylbcyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the us and europe and is in a pivotal phase  clinical trial for the treatment of niemannpick disease type c sucampo has an option for the north american rights to cpp xsulindac which is in phase  development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the us a global company sucampo is headquartered in rockville maryland and has operations in japan and switzerland matthias alder about us overview executive team board of directors technology overview abstracts  publications investors news and events press releases events careers contact us executive team we share a passion for delivering new treatments which offer substantial benefits for patients drawing upon our depth of experience and diversity of skills autolus is committed to building a leading tcell therapy company matthias aldersvp chief business officer and general counsel matthias alder joined autolus as chief business officer and general counsel in july  previously he served as executive vice president business development and licensing of sucampo pharmaceuticals inc from october  to march  and as general counsel and corporate secretary of the company from may  to june  during his tenure at sucampo matthias established a late stage development pipeline in orphan and rare diseases through acquisitions and strategic collaborations and improved the top and bottom line of the company through the acquisition of the japanese manufacturer of its only revenueproducing product prior to joining sucampo he served as executive vice president of corporate development and legal affairs and corporate secretary at cytos biotechnology ag a biopharmaceutical company focused on the development of targeted immunotherapies from  to october  from  to  matthias held various executive management roles at micromet inc serving as senior vice president administration general counsel and secretary at the time of the acquisition of micromet by amgen in  earlier in his career matthias was a partner in the life sciences transactions practice at cooley llp from  to  after joining the firm as an associate in  from novartis where he was inhouse counsel for its pharmaceutical business matthias holds law degrees from the university of basel and the university of miami and is qualified to practice law in switzerland and the united states matthias alder  former executive vice president general counsel  corporate secretary at sucampo pharmaceuticals inc news home advertising board and executive moves energy health care hedge funds m  a private equity technology you have    free profiles   left this month    start your free trial ➤ hey we noticed youre a relsci pro subscriber would you like to view the page there view on relsci pro ➤ email linkedin facebook google tweet reddit permalink matthias alder former executive vice president general counsel  corporate secretary at sucampo pharmaceuticals inc overview in the news relationships paths education career history boards  committees political donations public holdings transactions matthias alder former executive vice president general counsel  corporate secretary at sucampo pharmaceuticals inc overview age  born  notable companies sucampo pharmaceuticals inc amgen rockville inc board seats  number of relationships this person is connected to  people in the news see more awp ots original text service october   ots news cytos biotechnology ag  dgapadhoc cytos biotechnology  washington business journal october   sucampo hires former zyngenia chief peter kiener as cso pr newswire april   cytos biotechnology ltd reports first quarter  financial resultsand recent development pr newswire april   cytos biotechnology ltd reports first quarter  financial results and recent development pr newswire march   cytos biotechnology strengthens management team see full news coverage and complete stories with relsci professional create your news feed see more relationships see details brian f leaf partner at cooley llp christian e plaza partner at cooley llp darren k destefano partner at cooley llp christian itin chairman  chief executive officer at autolus ltd ken krisko partner at cooley llp howard morse partner at cooley llp david walsh partner at cooley llp daniel p meehan partner at kirkland  ellis llp shannon gallagherbolton chief human resources officer at cooley llp ashlie a lawton former associate at cooley llp see  more listings with relsci professional start my free trial ➤ see  more paths to matthias alder matthias alder you connections via relationship science matthias alder sync your contacts to see how you can connect with matthias alder start my free trial ➤ see more educational background   class of   university of basel the university of basel is the oldest university in switzerland founded upon the initiative of local citizens in  the university of basel is a modern and attractive center of teaching learning and research situated in the heart of basel the university of basel has been selfmanaged since  whilst remaining under the jurisdiction of the cantons of baselstadt and basellandschaft it provides committed individuals from all over the world a strong academic community and an inspiring work environment it employs nearly  people and its annual budget is around chf  million the university of basel is a classic university covering almost all fields of study from ancient studies to zoology the university of basel is a rather small university in european standards with around  students including  doctoral students as of  around  professors and  lecturers provide an excellent education and encourage independent thinking and responsible action the proportion of female students is   and rising  and one of five students come from abroad the university of basel seeks top performance in research teaching and service for years it is among the  best universities in the world and in the germanspeaking world it is one of the top ten law  university of miami  school of law the university of miami school of law founded in  is the law school of the university of miami located in coral gables florida in the united states the school graduated its first class of  students in  the university of miami school of law also offers extensive public interest programs and opportunities including the center for ethics and public service that offers inhouse clinics and educational programs including the children and youth law clinic health and elder law clinic and corporate  professional responsibility program the hope public interest resource center at the university of miami school of law gives students the opportunity to get involved in over  different projects each year reaching various underserved and atrisk populations locally nationally and abroadthe university of miami school of law is located on the main campus of the university of miami in coral gables just six miles southeast of miami the th largest metropolitan area in the nation the school of law is centered around a central courtyard called the bricks the law library has a collection of over  volumes in print and microform and subscribes to a large and everexpanding list of electronic resources career history executive vice president general counsel  corporate secretary    sucampo pharmaceuticals inc sucampo pharmaceuticals inc is a biopharmaceutical company which is engaged in developing identifying acquiring and bringing medicines that meet unmet medical needs it focuses on gastroenterology ophthalmology and oncologyrelated disorders the companys product pipeline includes amitiza for the treatment of chronic idiopathic constipation in adults irritable bowel syndrome with constipation in adult women opioidinduced constipation in patients with chronic noncancer pain chronic constipation and pediatric functional constipation its product pipeline also consists of unoprostone isopropyl which is in phase iii trial for the treatment of retinitis pigmentosa and in preclinical stage for the treatment of geographic atrophy and cobiprostone that has completed phase ib trial for the treatment of oral mucositis as well as in phase ii trial for the treatment of nonerosive reflux diseases sucampo pharmaceuticals was founded by dr ryuji ueno and dr sachiko kuno on december   and is headquartered in bethesda md secretary  executive vice presidentcorporate development    cytos biotechnology ag cytos biotechnology ag engages in the development and commercialization of biopharmaceutical products the company was founded by wolfgang a renner james e bailey and hans m eppenberger in february  and is headquartered in zurich switzerland secretary senior vice presidentadministration  general counsel    amgen rockville inc amgen rockville inc develops and commercializes antibodybased products its product development pipeline includes novel antibodies generated with its bite antibody platform as well as conventional monoclonal antibodies the company was founded in  and is headquartered in rockville md partner    cooley llp cooley llp is a provider of strategic litigation and business transaction services and is a representative of private and public companies financial institutions venture capital firms and nonprofit organizations the company was founded in  and is headquartered in new york ny counsel prior novartis inc novartis is dedicated to providing healthcare solutions that address the evolving needs of patients and societies worldwide their focus is on patients they provide innovative products to treat and prevent diseases expand access to critical medicines ease suffering and improve quality of life with more than  associates operating in  countries novartis is the only company with leadership positions in patented and generic pharmaceuticals vaccines and otc medicines boards  committees corporate boards ▾ secretary senior vice presidentadministration  general counsel prior amgen rockville inc amgen rockville inc develops and commercializes antibodybased products its product development pipeline includes novel antibodies generated with its bite antibody platform as well as conventional monoclonal antibodies the company was founded in  and is headquartered in rockville md political donations   barack obama former president of united states   dnc service corp dnc service corp operates a political party it is an organization which raises fund for the democratic party which has been a part of the us political landscape the company plans the presidential nominating convention promotes candidates from the local to the national level and sets the party platform dnc service was founded in  and is located in washington dc   john kerry former senator from massachusetts public holdings restricted data only for relsci professional users start my free trial ➤ see more transactions details hidden sucampo pharmaceuticals inc sucampo pharma llc purchase rtech ueno ltd details hidden amgen inc purchases amgen rockville inc other affiliations matthias alder is affiliated with sucampo pharmaceuticals inc cytos biotechnology ag amgen rockville inc cooley llp novartis inc amgen rockville inc youve reached your  free profiles limit this month upgrade to relsci pro today to enjoy unlimited article views and much more start my free trial ➤ still not convinced check out our full listing of features here are you a relsci pro subscriber login to relsci pro  ➤ not a pro subscriber log in here to manage your alerts keep me signed in login  ➤ forgot your password i have read the lexisnexis terms  conditions sign me up  ➤ alder matthias top holdings whalewisdom search all search f filers only search sec filer search stocks only search mgmt inv cos only etfs only search active alder matthias • bethesda md how do i update this listing alder matthias is based out of bethesda whalewisdom has at least  insider transactions form  in our database for alder matthias summary dg insider form  create email alert × email notification log in or signup to see more advanced email alert options such as selecting any type of sec form multiple filers or classes of filers and much more or to simply have an email sent to you whenever we receive a new f filing from alder matthias enter your email address below and choose submit your email cancel contact info alder matthias co micromet inc bethesda md     business phone   sec sic codebiological products no disgnostic substances recent sec filings  filed on   filed on   filed on   filed on   filed on   filed on   filed on   filed on   filed on   filed on  schedule d and g events since  subscription required form   nonderivative insider transactions since  loading elevate your investments try it for free matthias alder   facebook facebook？english us한국어français francebahasa indonesiapolskiespañolportuguês brasildeutschitalianomessengerfacebook liteinstagramcookie facebook   matthias s alder  arlington va  intelius sign in we found matthias s alder in arlington va matthias s alder intelius found that matthias s alder is a male between  and  years old from arlington va we have connected them to  addresses  phones and  relatives or associates get report now age matthias s alder is in his s matthias has lived in arlington va menlo park ca miami fl matthiass relatives janice alder marcus alder marianne alder matthias s alder zodiac signcapricorn gendermale professional status executive vice president business development  licensing at sucampo pharmaceuticals  inc get report now want to know more about matthias get a comprehensive background report find full phone numbers and other contact information when available all from billions of available public records continue below for more details about matthias or use our people search engine to find others get background check on matthias s alder get a criminal check on matthias s alder get a public record report on matthias s alder get a people search report on matthias s alder matthias s alders contact information known cities lived in find out where matthias s alder has lived as well as matthias s alders phone numbers and email addresses matthias s alder has lived in  states virginia address for matthias s alder   s n arlington va has lived in arlington va menlo park ca get full address report phone numbers associated with matthias s alder    arlington va    bethesda md    bethesda md get full phone report email addresses associated with matthias s alder mrcom amcom mrcom get email report matthias s alders education information known schools attended learn about matthias s alders academic history find out which schools matthias s alder attended the dates attended as well as the degrees matthias s alder received the following data is not guaranteed for accuracy and should not be used for employment insurance credit eligibility or for any other purpose covered under the fair credit reporting act matthias s alder has attended  schools university of miami  –  matthias s alder has a llm in international and comparative law university of miami  –  matthias s alder has a llm in international and comparative law university of miami  –  matthias s alder has a llm international and comparative law in international and comparative law  –  matthias s alder has a liciur in law  –  matthias s alder has a liciur law in law university of basel  –  matthias s alder has a liciur in law university of basel  –  matthias s alder has a liciur in law university of basel  –  matthias s alder has a liciur in law matthias s alders professional information information regarding matthias s alders professional history find out previous places matthias s alder has worked as well as dates employed the following data is not guaranteed for accuracy and should not be used for employment insurance credit eligibility or for any other purpose covered under the fair credit reporting act matthias s alder has worked at  places company sucampo pharmaceuticals  inc title executive vice president business development  licensing company micromet  inc title president matthias s alders experience title executive vice president business development  licensing company sucampo pharmaceuticals  inc job details company size  mil to less than  mil  employee range  to less than  title president company micromet  inc job details company size  mil to less than  mil  employee range  to less than  additional professional information on matthias s alder see matthias s alders linkedin profile matthias s alders social network and potential email matches find out potential social network profiles and potential email usernamed for matthias s alder matthias s alders known social networks and potential email matches find all of matthias s alders social network profiles get full report search social networks including facebook linkedin myspace google twitter yahoo jigsaw zoominfo and more potential email matches matthias alder username matches matthiasalder aldermatthias matthiasalder aldermatthias matthiasalder aldermatthias matthiasalder aldermatthias malder popular email services gmailcom aolcom yahoocom comcastnet hotmailcom msncom rocketmailcom attnet sbcglobalnet ymailcom facebookcom mailcom bellsouthnet livecom earthlinknet coxnet prodigynet mecom peoplepccom junocom rediffmailcom mindspringcom comcastcom charternet outlookcom all trademarks product names company names or logos on this page are the property of their respective owners related people searches m alder intelius is a leading provider of public data about people and their connections to others intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fair credit reporting act fcra this site should not be used to determine an individual’s eligibility for credit insurance employment housing or any other purpose covered by the fcra for employment or tenant screening services please visit our partner talentwise about us site map about our reports blog help contact us   –  peopleconnect inc dba intelius all rights reserved privacy policy  updated terms of service  updated what is the fcra the fair credit reporting act fcra is a federal law that promotes the accuracy fairness and privacy of information in the files of consumer reporting agencies intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fcra intelius reports cannot be used for background checks related to consumer credit insurance employment housing or any other purpose prohibited under the fcra you may not use any information obtained from intelius for any purpose covered by the fcra find out more about the fcra here scmp matthias a alder insider trades for sucampo pharmaceuticals inc cl a bulletin investor alert tokyo markets close in currencies europe markets london markets expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close sucampo pharmaceuticals inc cl a nasdaq scmp go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus sucampo pharmaceuticals inc cl a after hours  quotes are delayed by  min jul    pm scmp quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite todays close     change   day low day high    week low  week high   insider activity individual matthias a alder mr matthias a alder is executive vice president at sucampo pharmaceuticals inc mr alder was previously employed as secretary  executive vpcorporate development by cytos biotechnology ag secretary svpadministration  general counsel by amgen rockville inc partner by cooley godward llp partner by cooley llp managerhuman resources  quality assurance by amgen rockville inc counsel by cibageigy corp and counsel by novartis inc he received his graduate degree from the university of miami and a graduate degree from the university of basel transactions date shares transaction value     award at  per share      award at  per share      award at  per share      award at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      award at  per share      award at  per share      award at  per share      award at  per share      award at  per share      award at  per share  copyright  factset research systems inc all rights reserved source factset fundamentals officers and executives mr peter s greenleaf chairman  chief executive officer mr peter p pfreundschuh chief financial officer mr matthew maxwell donley evphuman resources  information technology dr peter alec kiener chief scientific officer dr peter lichtlen chief medical officer mr matthias a alder executive vice president dr jones woody bryan senior vice presidentbusiness development mr gregory a deener senior vpmarketing strategy  implementation dr karen l smith director mr paul r edick director mr timothy p walbert director dr robert jay spiegel director dr daniel p getman director ms elissa cote svpglobal strategic marketing ms silvia taylor svpinvestor relations  corporate communications mr alex driggs secretary  general counsel dr steven caffé senior vice presidentregulatory affairs mr john h johnson lead independent director ms maureen e oconnell independent director trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite tlt quoteszigmancomposite jnug x powered by log in  pm edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo open marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pone version of gop healthcare bills fails in senate vote pgeorge clooney and angelina jolie’s directorial projects could be the most soughtafter tickets at tiff pjohn mccain gives trump a win then gives senate an earful ppaypal earnings partnerships help but are benefits already priced in pamd puts intel in the crosshairs with fastandcheap threadripper chip pamd earnings give investors what they wanted now it must deliver phow about never avoid taking meetings with these troublesome coworkers phouse passes bill hitting russia with new sanctions pwsj interview trump doesnt rule out firing sessions pformer trump campaign chief manafort strikes deal to avoid public testimony pone depressing reason millions of people are locked out of the american dream phouse votes to prevent disgruntled customers from being able to sue their bank pthis quant pro and card counter says gambling can make you a better investor pbitcoin digital currencies retreat from records pthis is what it will take for bitcoin to become a legit currency pemerging markets fund manager favors bangladesh and kenya and avoids korea and taiwan puss thunderbolt fires warning shots at iranian vessel in gulf phere’s one trump fan who might make you some money pchegg shares sink after secondquarter loss pmccain returns to senate with strong comments on health care loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft loading your search results  peoplelookercom updating data on  live please help us narrow down your search all states alabama alaska arizona arkansas california colorado connecticut delaware district of columbia florida georgia hawaii idaho illinois indiana iowa kansas kentucky louisiana maine maryland massachusetts michigan minnesota mississippi missouri montana nebraska nevada new hampshire new jersey new mexico new york north carolina north dakota ohio oklahoma oregon pennsylvania rhode island south carolina south dakota tennessee texas utah vermont virginia washington west virginia wisconsin wyoming im not sure please enter a full name please help us narrow down your search first name please enter first name last name please enter last name people searching made easy  peoplelooker looking to find out about someone find information you may not get on google state alabama alaska arizona arkansas california colorado connecticut delaware district of columbia florida georgia hawaii idaho illinois indiana iowa kansas kentucky louisiana maine maryland massachusetts michigan minnesota mississippi missouri montana nebraska nevada new hampshire new jersey new mexico new york north carolina north dakota ohio oklahoma oregon pennsylvania rhode island south carolina south dakota tennessee texas utah vermont virginia washington west virginia wisconsin wyoming search we respect your privacy weve run over  background reports successful background reports access premium public records quickly search public records that could otherwise take you weeks or months to collect find friends relatives neighbors or even yourself comprehensive people search reports may contain names criminal records date of birth phone numbers addresses court records relatives email addresses much more names criminal records date of birth relatives email addresses phone numbers addresses court records much more the new way to find people more than a regular search engine its the quick and easy way to look people up do a deep public record search to uncover the important information youre looking for now youll never have to search someone on google again people searching made easy  peoplelooker looking to find out about someone find information you may not get on google state alabama alaska arizona arkansas california colorado connecticut delaware district of columbia florida georgia hawaii idaho illinois indiana iowa kansas kentucky louisiana maine maryland massachusetts michigan minnesota mississippi missouri montana nebraska nevada new hampshire new jersey new mexico new york north carolina north dakota ohio oklahoma oregon pennsylvania rhode island south carolina south dakota tennessee texas utah vermont virginia washington west virginia wisconsin wyoming search we respect your privacy weve run over  background reports successful background reports access premium public records quickly search public records that could otherwise take you weeks or months to collect find friends relatives neighbors or even yourself comprehensive people search reports may contain names criminal records date of birth phone numbers addresses court records relatives email addresses much more names criminal records date of birth relatives email addresses phone numbers addresses court records much more the new way to find people more than a regular search engine its the quick and easy way to look people up do a deep public record search to uncover the important information youre looking for now youll never have to search someone on google again people searching made easy  peoplelooker looking to find out about someone find information you may not get on google state alabama alaska arizona arkansas california colorado connecticut delaware district of columbia florida georgia hawaii idaho illinois indiana iowa kansas kentucky louisiana maine maryland massachusetts michigan minnesota mississippi missouri montana nebraska nevada new hampshire new jersey new mexico new york north carolina north dakota ohio oklahoma oregon pennsylvania rhode island south carolina south dakota tennessee texas utah vermont virginia washington west virginia wisconsin wyoming search we respect your privacy weve run over  background reports successful background reports access premium public records quickly search public records that could otherwise take you weeks or months to collect find friends relatives neighbors or even yourself comprehensive people search reports may contain names criminal records date of birth phone numbers addresses court records relatives email addresses much more names criminal records date of birth relatives email addresses phone numbers addresses court records much more the new way to find people more than a regular search engine its the quick and easy way to look people up do a deep public record search to uncover the important information youre looking for now youll never have to search someone on google again people searching made easy  peoplelooker looking to find out about someone find information you may not get on google state alabama alaska arizona arkansas california colorado connecticut delaware district of columbia florida georgia hawaii idaho illinois indiana iowa kansas kentucky louisiana maine maryland massachusetts michigan minnesota mississippi missouri montana nebraska nevada new hampshire new jersey new mexico new york north carolina north dakota ohio oklahoma oregon pennsylvania rhode island south carolina south dakota tennessee texas utah vermont virginia washington west virginia wisconsin wyoming search we respect your privacy weve run over  background reports successful background reports access premium public records quickly search public records that could otherwise take you weeks or months to collect find friends relatives neighbors or even yourself comprehensive people search reports may contain names criminal records date of birth phone numbers addresses court records relatives email addresses much more names criminal records date of birth relatives email addresses phone numbers addresses court records much more the new way to find people more than a regular search engine its the quick and easy way to look people up do a deep public record search to uncover the important information youre looking for now youll never have to search someone on google again